除了国内,兆科眼科还盯上了海外市场。得益于对外授权收入增加,兆科眼科(06622.HK)业绩大增。根据3月24日晚间披露的2024年业绩公告,2024年,公司录得收益6930万元,同比增长268.6%;年内亏损2.37亿元,上年同期为亏损3.85亿元,同比减亏。针对后续产品商业化等事宜,兆科眼科方面告诉时代财经,公司正在积极为预计于不久将来取得批准的疗效显著药物进行商业化准备,公司已建立核心商业...
Source Link除了国内,兆科眼科还盯上了海外市场。得益于对外授权收入增加,兆科眼科(06622.HK)业绩大增。根据3月24日晚间披露的2024年业绩公告,2024年,公司录得收益6930万元,同比增长268.6%;年内亏损2.37亿元,上年同期为亏损3.85亿元,同比减亏。针对后续产品商业化等事宜,兆科眼科方面告诉时代财经,公司正在积极为预计于不久将来取得批准的疗效显著药物进行商业化准备,公司已建立核心商业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.